{"id":"NCT01894919","sponsor":"Novartis Vaccines","briefTitle":"Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28","officialTitle":"A Phase IIIb, Open Label, Multi Center Extension Study of V72_28 to Assess Antibody Persistence, and the Safety and Tolerability of a Booster Dose After the Completion of the Vaccination Course in Study V72_28","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06","primaryCompletion":"2015-09","completion":"2015-11","firstPosted":"2013-07-10","resultsPosted":"2018-12-07","lastUpdate":"2021-11-30"},"enrollment":851,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Meningoccocal Disease","Meningococcal Meningitis"],"interventions":[{"type":"BIOLOGICAL","name":"Bexsero® vaccine (1 dose at study month zero)","otherNames":[]},{"type":"BIOLOGICAL","name":"Bexsero® vaccine (2 doses 1 month apart)","otherNames":[]}],"arms":[{"label":"2H3H511_V","type":"EXPERIMENTAL"},{"label":"2H3H511_NV","type":"NO_INTERVENTION"},{"label":"3H5_11_V","type":"EXPERIMENTAL"},{"label":"3H5_11_NV","type":"NO_INTERVENTION"},{"label":"68_11_V","type":"EXPERIMENTAL"},{"label":"68_11_NV","type":"NO_INTERVENTION"},{"label":"02_2_5_V","type":"EXPERIMENTAL"},{"label":"02_2_5_NV","type":"NO_INTERVENTION"},{"label":"02_6_10_V","type":"EXPERIMENTAL"},{"label":"02_6_10_NV","type":"NO_INTERVENTION"},{"label":"NAIVE 123","type":"EXPERIMENTAL"},{"label":"NAIVE_4A","type":"EXPERIMENTAL"},{"label":"NAIVE_4B","type":"EXPERIMENTAL"}],"summary":"The aim of this extension study is to explore the antibody persistence 24 to 36 months after the last dose of vaccine, in infants that received a two or three dose primary series plus a booster dose at 11 months of age, of the Novartis meningococcal B vaccine (Bexsero®) in groups I to III of the parent V72\\_28 study.\n\nThis study will also explore the antibody persistence 24 to 36 months after two catch-up doses of the Novartis meningococcal B vaccine (Bexsero®) administered in children (2 to 10 years old) in group IV of the parent V72\\_28 study.","primaryOutcome":{"measure":"Percentage of Subjects With Human Serum Bactericidal Activity Titers (hSBA) ≥ 4 or ≥ 5 Against Neisseria Meningitidis (N. Meningitidis) Serogroup B Strains","timeFrame":"24-36 months after booster dose in the parent study; baseline for vaccine-naïve subjects","effectByArm":[{"arm":"2H3H511","deltaMin":51,"sd":null},{"arm":"3H5_11","deltaMin":53,"sd":null},{"arm":"68_11","deltaMin":61,"sd":null},{"arm":"NAIVE 123","deltaMin":38,"sd":null},{"arm":"02_2_5","deltaMin":52,"sd":null},{"arm":"NAIVE_4A","deltaMin":27,"sd":null},{"arm":"02_6_10","deltaMin":58,"sd":null},{"arm":"NAIVE_4B","deltaMin":20,"sd":null}],"pValues":[]},"eligibility":{"minAge":"35 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":17,"countries":["Hungary","Spain"]},"refs":{"pmids":["29253560"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":97},"commonTop":["Injection site pain","Injection site erythema","Injection site swelling","Injection site induration","Irritability"]}}